Spinal Muscular Atrophy Treatment Market Report 2025 (Global Edition)

Global Spinal Muscular Atrophy Treatment Market Report 2025 Market Size Split by Product (Nusinersen, Onasemnogen Abeparvovec), by Treatment (Gene Therapy, Disease-modifying drugs), by Age Group (Infa...

Spinal Muscular Atrophy Treatment Market Report Description

We have various report editions of Spinal Muscular Atrophy Treatment Market, hence please contact our sales team and author directly to obtain/purchase a desired Edition eg, Global Edition, Regional Edition, Country Specific Report Edition, Company Profiles, Forecast Edition, etc. Request for your Free Sample PDF/Online Access.

Spinal Muscular Atrophy Treatment Market Insights Video

Competitive Landscape of the Spinal Muscular Atrophy Treatment Market

The competitive landscape of the Spinal Muscular Atrophy (SMA) Treatment Market is characterized by major pharmaceutical companies such as Novartis, Biogen, and Roche, which lead in the development and commercialization of SMA therapies. Additionally, emerging biotech firms like AveXis, PTC Therapeutics, and Ionis Pharmaceuticals are gaining prominence with innovative approaches. Collaboration and strategic partnerships among these companies drive research, development, and market penetration. This competitive environment fosters innovation and diversity in treatment options for SMA patients.

July 2021: Roche introduced Evrysdi, a prescription medication, to the Indian market. This drug is indicated for the treatment of spinal muscular atrophy (SMA) in both adult patients and children aged two months and above. Source: https://www.roche.com/solutions/pharma/productid-423934d3-782a-4102-884a-1db9fafc8ae8#:~:text=Evrysdi%20(risdiplam)%20%E2%96%BC,neuron%20(SMN)%20protein%20deficiency. )

Top Companies Market Share in Spinal Muscular Atrophy Treatment Industry: (In no particular order of Rank)

• Novartis (Switzerland)
• Biogen (United States)
• Roche (Switzerland)
• AveXis
• a Novartis Company (United States)
• PTC Therapeutics (United States)
• Cytokinetics (United States)
• Scholar Rock (United States)
• Astellas Pharma (Japan)
• Genentech
• a Roche Company (United States)
• Ionis Pharmaceuticals (United States)
• Confidential Data
• Access The Paid Version
• Data Hidden

*List of Second Tier Companies, List of Third Tier/ Start-up Companies (Inquire with sales executive) Request Any Company Profile for Preview Purpose OR Data Validation!

If any Company(ies) of your interest has/have not been disclosed in the above list then please let us know the same so that we will check the data availability in our database and provide you the confirmation or include it in the final deliverables.

Regional Analysis of the Spinal Muscular Atrophy Treatment Market

Which Region Dominates the Spinal Muscular Atrophy Treatment Market in 2024?

According to Cognitive Market Research, North America dominates the Spinal Muscular Atrophy (SMA) Treatment Market due to several factors. The region boasts advanced healthcare infrastructure, high awareness levels, and robust research and development activities. Moreover, key pharmaceutical companies and biotech firms in North America are at the forefront of SMA treatment innovation. Additionally, favorable reimbursement policies and government initiatives further contribute to the region's leading market position, making it the preferred destination for SMA treatment advancements and investments.

Which Region is Expanding at the Fastest CAGR?

The Asia Pacific region is experiencing the fastest Compound Annual Growth Rate (CAGR) in the Spinal Muscular Atrophy (SMA) Treatment Market due to several factors. These include increasing awareness about SMA, improving healthcare infrastructure, rising healthcare expenditure, and a growing emphasis on rare disease treatments. Additionally, collaborations between global pharmaceutical companies and local biotech firms, along with government initiatives to improve access to innovative therapies, are driving market growth in the Asia Pacific region.

 

The current report Scope analyzes Spinal Muscular Atrophy Treatment Market on 5 major region Split (In case you wish to acquire a specific region edition (more granular data) or any country Edition data then please write us on info@cognitivemarketresearch.com

• North America (United States, Canada, Mexico)
• Europe (United Kingdom, France, Germany, Italy, Russia, Spain, Sweden, Denmark, Netherlands, Switzerland, Belgium)
• Asia-Pacific (China, Japan, Korea, India, Australia, Philippines, Singapore, Malaysia, Thailand, Indonesia, Rest of APAC)
• South America (Brazil, Argentina, Colombia, Peru, Chile, Rest of South America)
• Middle East and Africa (Saudi Arabia, Turkey, Nigeria, UAE, Egypt, South Africa, GCC Countries, Rest of MEA)

The above graph is for illustrative purposes only.

North America Spinal Muscular Atrophy Treatment

According to Cognitive Market Research, the global Spinal Muscular Atrophy Treatment market size was estimated at USD 4518.20 Million, out of which North America held the major market of more than 40% of the global revenue with a market size of USD 1807.28 million in 2024 and will grow at a compound annual growth rate (CAGR) of 5.2% from 2024 to 2031. The North America market is growing in the Spinal Muscular Atrophy (SMA) Treatment Market due to factors such as advanced healthcare infrastructure, high awareness levels, robust research and development activities, and favorable reimbursement policies. Additionally, key pharmaceutical companies and biotech firms in North America lead in SMA treatment innovation, attracting investments and driving advancements in therapies. These factors collectively contribute to the region's growing dominance in the SMA treatment market.

• According to Cognitive Market Research, the US had a major share in the Spinal Muscular Atrophy Treatment market with a market size of USD 1425.94 million in 2024 and is projected to grow at a CAGR of 5.0% during the forecast period. The demand is amplified by the nation's advanced healthcare infrastructure.
• The Canada Spinal Muscular Atrophy Treatment market had a market share of USD 216.87 million in 2024 and is projected to grow at a CAGR of 6.0% during the forecast period. This is due to high awareness levels.
• The Mexico Spinal Muscular Atrophy Treatment market is projected to witness growth at a CAGR of 5.7% during the forecast period, with a market size of USD 164.46 million in 2024.

Europe Spinal Muscular Atrophy Treatment

According to Cognitive Market Research, the global Spinal Muscular Atrophy Treatment market size was estimated at USD 4518.20 Million out of which Europe held the market of more than 30% of the global revenue with a market size of USD 1355.46 million in 2024 and will grow at a compound annual growth rate (CAGR) of 5.5% from 2024 to 2031. The European market is growing in the Spinal Muscular Atrophy (SMA) Treatment Market due to factors such as increasing awareness, favorable regulatory environment, and expanding treatment options. Additionally, collaborations between pharmaceutical companies, research institutions, and patient advocacy groups drive innovation and market expansion. Furthermore, the availability of advanced healthcare infrastructure and high-quality medical services across Europe facilitates access to SMA treatments, contributing to the region's growth in the market.

• The United Kingdom Spinal Muscular Atrophy Treatment market had a market share of USD 227.72 million in 2024 and is projected to grow at a CAGR of 6.3% during the forecast period. In the UK, Spinal Muscular Atrophy Treatment sales witness an upswing due to advanced healthcare infrastructure.
• The France Spinal Muscular Atrophy Treatment market is projected to witness growth at a CAGR of 4.7% during the forecast period, with a market size of USD 124.70 million in 2024.
• According to Cognitive Market Research, the Germany Spinal Muscular Atrophy Treatment market size was valued at USD 268.38 million in 2024 and is projected to grow at a CAGR of 5.7% during the forecast period. In Germany, Spinal Muscular Atrophy Treatment sales surged due to increasing awareness.
• The Italy Spinal Muscular Atrophy Treatment market is projected to witness growth at a CAGR of 4.9% during the forecast period, with a market size of USD 116.57 million in 2024.
• The Russia Spinal Muscular Atrophy Treatment market is projected to witness growth at a CAGR of 4.5% during the forecast period, with a market size of USD 210.10 million in 2024.
• The Spain Spinal Muscular Atrophy Treatment market is projected to witness growth at a CAGR of 4.6% during the forecast period with a market size of USD 111.15 million in 2024
• The Luxembourg Spinal Muscular Atrophy Treatment market is projected to witness growth at a CAGR of 5.6% during the forecast period, with a market size of USD 42.02 million in 2024.
• The Portugal Spinal Muscular Atrophy Treatment market is projected to witness growth at a CAGR of 5.3% during the forecast period, with a market size of USD 28.46 million in 2024.
• The Greece Spinal Muscular Atrophy Treatment market is projected to witness growth at a CAGR of 5.8% during the forecast period, with a market size of USD 16.47 million in 2024.
• Rest of Europe's Spinal Muscular Atrophy Treatment market is projected to witness growth at a CAGR of 4.2% during the forecast period, with a market size of USD 210.10 million in 2024.

Asia Pacific Spinal Muscular Atrophy Treatment

According to Cognitive Market Research, the global Spinal Muscular Atrophy Treatment market size was estimated at USD 4518.20 Million, out of which Asia Pacific held the market of around 23% of the global revenue with a market size of USD 1039.19 million in 2024 and will grow at a compound annual growth rate (CAGR) of 9.0% from 2024 to 2031. The Asia Pacific market is experiencing growth in the Spinal Muscular Atrophy (SMA) Treatment Market due to increasing healthcare infrastructure, rising awareness, and improving access to innovative therapies. Additionally, partnerships between global pharmaceutical companies and local biotech firms, coupled with government initiatives to address rare diseases, are driving market expansion. Furthermore, the region's large population base and growing healthcare expenditure contribute to the increasing demand for SMA treatments in Asia Pacific.

• According to Cognitive Market Research, the China Spinal Muscular Atrophy Treatment market size was valued at USD 467.63 million in 2024 and is projected to grow at a CAGR of 8.5% during the forecast period. Spinal Muscular Atrophy Treatment sales surge in China due to region's large population base.
• The Japan Spinal Muscular Atrophy Treatment market is projected to witness growth at a CAGR of 7.5% during the forecast period, with a market size of USD 143.41 million in 2024.
• The India Spinal Muscular Atrophy Treatment market had a market share of USD 124.70 million in 2024 and is projected to grow at a CAGR of 10.8% during the forecast period. This is due to increasing healthcare infrastructure.
• The South Korea Spinal Muscular Atrophy Treatment market is projected to witness growth at a CAGR of 8.1% during the forecast period, with a market size of USD 103.92 million in 2024.
• The Australia Spinal Muscular Atrophy Treatment market is projected to witness growth at a CAGR of 8.7% during the forecast period, with a market size of USD 54.04 million in 2024.
• The South East Asia Spinal Muscular Atrophy Treatment market is projected to witness growth at a CAGR of 10.0% during the forecast period, with a market size of USD 71.70 million in 2024.
• The Rest of Asia Pacific Spinal Muscular Atrophy Treatment market is projected to witness growth at a CAGR of 8.8% during the forecast period, with a market size of USD 73.78 million in 2024.

South America Spinal Muscular Atrophy Treatment

According to Cognitive Market Research, the global Spinal Muscular Atrophy Treatment market size was estimated at USD 4518.20 Million out of which Latin America market of more than 5% of the global revenue with a market size of USD 225.91 million in 2024 and will grow at a compound annual growth rate (CAGR) of 6.4% from 2024 to 2031. The Latin America market is growing in the Spinal Muscular Atrophy (SMA) Treatment Market due to improving healthcare infrastructure, increasing awareness, and expanding access to SMA treatments. Moreover, collaborations between international pharmaceutical companies and local healthcare providers drive innovation and market penetration. Additionally, governmental initiatives to address rare diseases and enhance healthcare services contribute to the growth of the SMA treatment market in Latin America.

• According to Cognitive Market Research, the Brazil Spinal Muscular Atrophy Treatment market size was valued at USD 96.69 million in 2024 and is projected to grow at a CAGR of 7.0% during the forecast period. Spinal Muscular Atrophy Treatment sales flourish in Brazil due to improving healthcare infrastructure.
• Argentina Spinal Muscular Atrophy Treatment market had a market share of USD 37.95 million in 2024 and is projected to grow at a CAGR of 7.3% during the forecast period. This is due to increasing awareness and expanding access to SMA treatments.
• Colombia Spinal Muscular Atrophy Treatment market is projected to witness growth at a CAGR of 6.2% during the forecast period with a market size of USD 20.11 million in 2024.
• Peru Spinal Muscular Atrophy Treatment market is projected to witness growth at a CAGR of 6.6% during the forecast period with a market size of USD 18.52 million in 2024.
• Chile Spinal Muscular Atrophy Treatment market is projected to witness growth at a CAGR of 6.7% during the forecast period with a market size of USD 16.27 million in 2024.
• The Rest of Latin America Spinal Muscular Atrophy Treatment market is projected to witness growth at a CAGR of 5.5% during the forecast period, with a market size of USD 36.37 million in 2024.

Middle East Spinal Muscular Atrophy Treatment

According to Cognitive Market Research, the global Spinal Muscular Atrophy Treatment market size was estimated at USD 4518.20 Million, out of which the Middle East and Africa held the major market of around 2% of the global revenue with a market size of USD 90.36 million in 2024 and will grow at a compound annual growth rate (CAGR) of 6.7% from 2024 to 2031. The Middle East and Africa (MEA) market is growing in the Spinal Muscular Atrophy (SMA) Treatment Market due to improving healthcare infrastructure, rising awareness of rare diseases, and increasing investments in medical research and development. Additionally, collaborations between international pharmaceutical companies and local healthcare providers facilitate access to innovative SMA treatments in the region. Furthermore, governmental initiatives aimed at enhancing healthcare services contribute to the growth of the SMA treatment market in MEA.

• The GCC Countries Spinal Muscular Atrophy Treatment market is projected to witness growth at a CAGR of 7.5% during the forecast period with a market size of USD 38.68 million in 2024. Spinal Muscular Atrophy Treatment sales flourish due to improving healthcare infrastructure.
• The Egypt Spinal Muscular Atrophy Treatment market is projected to witness growth at a CAGR of 7.0% during the forecast period, with a market size of USD 9.49 million in 2024.
• The South Africa Spinal Muscular Atrophy Treatment market is projected to witness growth at a CAGR of 7.7% during the forecast period, with a market size of USD 14.28 million in 2024. Spinal Muscular Atrophy Treatment sales flourish in South Africa due to increasing investments in medical research.
• The Turkey Spinal Muscular Atrophy Treatment market is projected to witness growth at a CAGR of 6.2% during the forecast period, with a market size of USD 7.77 million in 2024.
• The Nigeria Spinal Muscular Atrophy Treatment market is projected to witness growth at a CAGR of 5.8% during the forecast period, with a market size of USD 9.49 million in 2024.
• The Rest of MEA Spinal Muscular Atrophy Treatment market is projected to witness growth at a CAGR of 5.7% during the forecast period, with a market size of USD 10.66 million in 2024.

Spinal Muscular Atrophy Treatment Market Analysis

How are Segments Performing in the Global Spinal Muscular Atrophy Treatment Market?

Spinal Muscular Atrophy Treatment Market Product Segment Analysis

According to Cognitive Market Research, Nusinersen stands out as the dominating category. Nusinersen, a product marketed under the brand name Spinraza, has captured the largest market share in the Spinal Muscular Atrophy (SMA) Treatment Market for several reasons. It was the first approved drug specifically targeting SMA, gaining early market entry and widespread adoption. Additionally, its proven efficacy in improving motor function and survival in SMA patients, along with favorable reimbursement policies in many regions, have contributed to its dominance in the market over other treatment options.

Onasemnogen Abeparvovec, marketed as Zolgensma, is experiencing the highest Compound Annual Growth Rate (CAGR) in the Spinal Muscular Atrophy (SMA) Treatment Market due to its innovative gene therapy approach. As a one-time treatment, it offers potential long-term benefits, attracting both patients and healthcare providers. Additionally, regulatory approvals and increasing adoption of gene therapy technologies contribute to its rapid growth. Despite its high cost, the promise of a potentially curative treatment for SMA drives its market expansion at a significant rate.

The above Chart is for representative purposes and does not depict actual sale statistics. Access/Request the quantitative data to understand the trends and dominating segment of Spinal Muscular Atrophy Treatment Industry. Request a Free Sample PDF!

Spinal Muscular Atrophy Treatment Market Treatment Segment Analysis

According to Cognitive Market Research, the dominating category is Gene Therapy. Gene therapy treatments have captured the largest market share in the Spinal Muscular Atrophy (SMA) Treatment Market due to their revolutionary approach to addressing the root cause of the disease. By directly targeting the underlying genetic mutation responsible for SMA, gene therapies offer the potential for long-term efficacy and even potential cures. Despite being relatively new and expensive, the promise of transformative outcomes and the increasing adoption of gene therapy technologies have propelled their dominance in the market.

Disease-modifying drugs are experiencing the highest Compound Annual Growth Rate (CAGR) in the Spinal Muscular Atrophy (SMA) Treatment Market due to their ability to modify the course of the disease and improve patient outcomes over time. Unlike symptomatic treatments, disease-modifying drugs target the underlying mechanisms of SMA, potentially offering long-term benefits. With advancements in research and development, coupled with increasing clinical evidence supporting their efficacy, these drugs are gaining traction and driving significant growth in the market.

The above Graph is for representation purposes only. This chart does not depict actual Market share.

Spinal Muscular Atrophy Treatment Age Group Segment Analysis

Age Group Segment Analysis

According to Cognitive Market Research, the dominating category is Infant. The infant age group has captured the largest market share in the Spinal Muscular Atrophy (SMA) Treatment Market due to several factors. Firstly, SMA symptoms typically manifest early in infancy, necessitating prompt intervention. Secondly, regulatory approvals for SMA treatments often prioritize this age group due to the severity of the disease at this stage. Additionally, the efficacy of treatments such as gene therapy and disease-modifying drugs is often more pronounced when administered early in the disease course, further driving their adoption in infants.

The adult age group is experiencing the highest Compound Annual Growth Rate (CAGR) in the Spinal Muscular Atrophy (SMA) Treatment Market due to several factors. Firstly, advancements in medical research have led to the development of therapies specifically tailored to address the needs of adult SMA patients. Additionally, increasing awareness and diagnosis rates among adults, along with expanding treatment options and improved access to healthcare, are driving the demand for SMA treatments in this demographic, contributing to its rapid market growth.

• Infant
• Adult

Spinal Muscular Atrophy Treatment disease_type_desc Segment Analysis

Disease Type Segment Analysis

According to Cognitive Market Research, the dominating category is Type 1 SMA. Type 1 SMA disease type has captured the largest market share in the Spinal Muscular Atrophy (SMA) Treatment Market due to its early onset and severe symptoms. Infants with Type 1 SMA require immediate intervention, making them a priority for treatment. Additionally, regulatory approvals and clinical trials often focus on Type 1 SMA due to its high morbidity and mortality rates. Consequently, treatment options, including gene therapy and disease-modifying drugs, are more extensively developed and available for this disease subtype, driving its dominance in the market.

Type 2 SMA disease type is experiencing the highest Compound Annual Growth Rate (CAGR) in the Spinal Muscular Atrophy (SMA) Treatment Market due to several factors. Unlike Type 1 SMA, which has historically received more attention, advancements in medical research and therapeutic development have increasingly focused on addressing the needs of Type 2 SMA patients. Additionally, the milder progression of symptoms in Type 2 SMA allows for a broader range of treatment options, driving its rapid market growth.

• Type 1 SMA
• Type 2 SMA
• Others

Spinal Muscular Atrophy Treatment Route of Administration Outlook: Segment Analysis

Route of Administration Segment Analysis

According to Cognitive Market Research, the dominating category is Oral. The oral route of administration has captured the largest market share in the Spinal Muscular Atrophy (SMA) Treatment Market due to its convenience and patient-friendly nature. Oral medications offer ease of administration, eliminating the need for invasive procedures such as injections or infusions. Additionally, oral formulations enhance patient compliance and adherence to treatment regimens, particularly in pediatric and elderly populations. As a result, oral SMA treatments have gained widespread acceptance, driving their dominance in the market.

The Parenteral Route of Administration is experiencing the highest Compound Annual Growth Rate (CAGR) in the Spinal Muscular Atrophy (SMA) Treatment Market due to several factors. Parenteral administration offers direct delivery of medications into the bloodstream, ensuring rapid onset of action and precise dosage control. Additionally, parenteral formulations are often preferred for biologic therapies and gene therapies, which are emerging as promising treatment options for SMA. These factors contribute to the rapid growth of parenteral administration in the SMA treatment market.

• Oral
• Parenteral

Spinal Muscular Atrophy Treatment end_user_desc Segment Analysis

End User Segment Analysis

According to Cognitive Market Research, the dominating category is Hospitals. Hospitals are the largest end user in the Spinal Muscular Atrophy (SMA) Treatment Market due to several factors. Hospitals serve as primary centers for SMA diagnosis, treatment, and management, providing a comprehensive range of medical services and specialized care. Additionally, hospitals house multidisciplinary teams of healthcare professionals, including neurologists, geneticists, and physical therapists, capable of addressing the complex needs of SMA patients. The availability of advanced medical equipment and infrastructure in hospitals further solidifies their dominance in SMA treatment provision.

The "Others" end user category is experiencing the highest Compound Annual Growth Rate (CAGR) in the Spinal Muscular Atrophy (SMA) Treatment Market due to increasing adoption of outpatient clinics, specialty clinics, and home healthcare settings for SMA treatment delivery. These alternative healthcare settings offer convenience, personalized care, and reduced healthcare costs compared to traditional hospital settings. Additionally, advancements in telemedicine and remote monitoring technologies have facilitated SMA treatment outside of traditional hospital settings, driving growth in the "Others" end user segment.

• Hospitals
• Others

Author's Detail

Anushka Gore

Research Associate at Cognitive Market Research

LinkedIn

Profile

Anushka Gore is a seasoned market researcher specializing in the dynamic landscape of the Pharmaceutical industry. With a keen analytical mind and a deep passion for healthcare advancements, she has dedicated herself unraveling the intricate market trends and consumer behaviors that shape the future of medical technologies and services.

Author's Conclusion